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MATRIX METALLOPROTEINASE AND TISSUE INHIBITOR OF
METALLOPROTEINASE ACTIVITY IN SYNOVIAL FLUID FROM HORSES
WITH POST-TRAUMATIC OSTEOARTHRITIS
T.N. Trumble y, D.M. Groschen y, K. Merritt z, M.P. Brown z. yUniv. of
Minnesota, St. Paul, MN, USA; zUniv. of Florida, Gainesville, FL, USA
Purpose: Matrix metalloproteinases (MMPs) are enzymes that are
responsible for degradation of the extracellular matrix of articular car-
tilage. Tissue inhibitors of metalloproteinases (TIMPs) are natural
inhibitors that bind 1:1 with MMPs blocking their actions. In general,
MMP activity has been shown to increase when cartilage damage is
present, whereas TIMP activity is variable. The objective of the current
study was to compare MMP and TIMP concentrations and their ratios in
synovial ﬂuid (SF) from horses with normal joints (controls) and those
with post-traumatic osteoarthritis (PTOA). Our hypothesis was that
MMP concentrations would be higher and TIMP concentrations would
be lower in joints with PTOA compared to controls, resulting in higher
MMP to TIMP ratios in injured horses. If so, this would account for less
regulation of MMP activity in injured joints, potentiating further
articular cartilage damage.
Methods: SF was taken from the metacarpophalangeal (n ¼ 11) and/or
carpal (n ¼ 10) joints from 19 horses (age range 2-14 years) that had
arthroscopic evidence of PTOA and from the metacarpophalangeal (n ¼
10) and/or carpal (n ¼ 4) joints from 12 control horses (age range 4-9
years) with radiographically and clinically normal joints. SF was asep-
tically collected by needle arthrocentesis without lavage, centrifuged,
and decanted. Commercially available multiplex assays (R&D Systems,
Minneapolis, MN) were used to measure MMP -1, -2, -3, -9, and -13
(Human MMP Magnetic Luminex Performance Assay) and TIMP -1, -2,
-3, and -4 (Human TIMP Magnetic Luminex Performance Assay 4-plex
kit) on a Luminex xMap technology based multiplex array system (Bio-
Plex 200 system, Bio-Rad Laboratories, Hercules, CA). SF was digested
with hyluronidase and then diluted at appropriate dilutions and were
run in duplicate (TIMPs) or triplicate (MMPs). MMP to TIMP ratios were
calculated for each group. Descriptive statistics were performed as well
as a Mann Whitney test to determine differences between PTOA horses
and controls. Spearman rank correlations were performed to determine
correlations between MMPs and TIMPs. P<0.05 was considered
signiﬁcant.
Results: Concentrations for MMP-2, MMP-3, and TIMP-2 were all sig-
niﬁcantly higher in SF from PTOA joints compared to control joints
(P<0.05). In addition, the MMP-2/TIMP-1, MMP-2/TIMP-4, and MMP-3/
TIMP-3 ratios were all signiﬁcantly higher in PTOA joints compared to
control joints (P<0.05). In PTOA joints, 9/17 (53%) samples had MMP-3
concentrations higher than 100 pg/mL compared to only 3/14 (21%) for
controls. In addition, in those PTOA horses in which MMP-3 concen-
trations were >100 pg/mL, 8/9 (89%) had MMP-1 concentrations >100
pg/mL, 7/9 (78%) had MMP-2 concentrations >0 pg/mL, 5/9 (56%) had
MMP-9 concentrations >100 pg/mL, and 3/9 (33%) had MMP-13 con-
centrations >0 pg/mL, whereas control horses with MMP-3 concen-
trations >100 pg/mL had no horses with MMP-1 concentrations >100
pg/mL, MMP-2 concentrations >0 pg/mL, MMP-9 concentrations >100
pg/mL, and MMP-13 concentrations >0 pg/mL. MMP-1 and MMP-3
were highly correlated (P<0.001; R ¼ 0.793) as was MMP-2 and TIMP-2
(P ¼ 0.002; R ¼ 0.716).
Conclusions: Post traumatic osteoarthritic joints have selectively
higher MMP and TIMP concentrations than control joints. In addition,
PTOA joints also have higher ratios of MMPs to TIMPs when examining
MMP-2 relative to TIMP-1 and -4, as well as MMP-3 relative to TIMP-3.
Most MMP concentrations were higher in PTOA joints than controls
while TIMP concentrations generally stayed the same or decreased
(except for TIMP-2). This indicates that when PTOA develops, TIMP
concentrations generally do not directly increase in response to
increased MMP concentrations. This could allow MMPs to further
degrade the extracellular matrix of articular cartilage. TIMP-2 was the
only TIMP to increase when PTOAwas present, which may be related to
its capability to drive the release and activation of MMP-2, as also
demonstrated by the correlation between MMP-2 and TIMP-2. In those
PTOA joints in which MMP-3 concentrations were >100 pg/mL, multi-
ple other MMP concentrations were elevated as well whereas no con-
trol samples followed this pattern. This demonstrates the likely
interplay between MMPs once PTOA develops where one MMP stim-
ulates the production and the activation of others to drive further car-
tilage degradation. SF analysis of MMPs and TIMPs as indirectbiomarkers of PTOA may prove to have value in monitoring the pro-
gression of OA, especially if combined with cytokines, chemokines, and
traditional biochemical biomarkers of OA.
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ASSOCIATION BETWEEN BIOCHEMICAL CARTILAGE MARKERS AND
CLINICAL SYMPTOMS IN PATIENTS WITH HIP OSTEOARTHRITIS:
COHORT STUDY WITH TWO-YEAR FOLLOW-UP
D.M. Dorleijn y, P.A. Luijsterburg y, A.C. Bay-Jensen z, A.S. Siebuhr z,
M. Karsdal z, R.M. Rozendaal y, P.K. Bos y, S.M. Bierma-Zeinstra y.
y Erasmus MC, Rotterdam, Netherlands; zNordic BioSci., Herlev, Denmark
Purpose: Biomarkers are deﬁned as characteristics that are objectively
measured and evaluated as an indicator of normal biological processes,
pathogenic processes, or pharmacologic responses to a therapeutic
intervention. The availability of biomarkers that can assist in diagnosing
early-stage OA, predicting OA progression, and assessing therapeutic
responses could improve early diagnosis and help monitor the effect of
OA treatment. The goal of this study was to assess the associations
between two urinary biomarkers (CTX-II and CIIM) and severity of hip
pain in patients with hip OA over a 2-year period, and establish whether
the level of these biomarkers at baseline could predict a speciﬁc course
of hip pain.
Methods: The study population consisted of primary care patients
diagnosed with hip OA (n ¼ 222) who participated in a prospective
randomized controlled trial that assessed the effect of glucosamine
sulfate (GOAL trial). Patients were eligible if they met one of the
American College of Rheumatology criteria for hip OA. Patients who had
undergone or were awaiting total hip replacement surgery and patients
with a Kellgren and Lawrence (KL) score of 4 were excluded. Patients
were also excluded if they had renal disease, liver disease, diabetes
mellitus, or were already taking glucosamine. The outcomes were level
of the biomarkers uCTX-II and uCIIM, and hip pain, measured with the
Western Ontario and McMasters University Osteoarthritis Index
(WOMAC) and with the Visual Analog Scale (VAS). All outcomes were
measured at baseline, and at 6, 12, 18, and 24 months follow-up.
Associations between level of and biomarkers and hip pain severity
were assessed using linear mixed-model analysis for repeated meas-
urements. Adjustments included: age, gender, body mass index, allo-
cated treatment, duration of hip complaints, type of OA and severity of
radiologic hip OA. A subgroup analysis was performed with patients
with minimal radiologic hip OA (KL<2) and patients with deﬁnite
radiologic hip OA (KL2). Using the 3-monthly repeated pain meas-
urements during 2-year follow-up, ﬁve distinct hip pain courses (tra-
jectories) were identiﬁed in the GOAL trial previously: mild pain,
moderate pain, high pain, regularly progressive pain, and highly pro-
gressive pain. These trajectories of hip pain were used as outcome to
investigate whether the level of biomarkers at baseline could predict
membership in one of the ﬁve trajectories using multinomial regression
analysis.
Results: The mean age of the 222 patients participating in the GOAL
trial was 63.4 (SD 9.0) years and 69.4% of patients were female. At
baseline, the meanWOMAC pain score was 34.2 (SD 23.1) and the mean
VAS pain scorewas 32.4 (SD 25.9). Themedian uCIIM pg/umol creat was
61.7 (IQR 51.5) and the median uCTX-II pg/umol creat was 332 (IQR
355).
At baseline, biomarkers for 197 (89%) patients were available for anal-
ysis, compared with 177 (80%) patients at 6-months follow-up, 190
(86%) at 12 months, 186 (84%) at 18 months and 187 (84%) patients at
24-months follow-up.
Patients in the highly progressive pain trajectory and the moderate pain
trajectory were more likely to have a higher loguCTX-II at baseline (OR
6.5; 95% CI 1.6-28.2 and OR 4.8; 95%CI 1.0-22.8, respectively) than
patients in the mild pain trajectory.
Neither loguCTX-II nor loguCIIM were cross-sectionally associated with
WOMAC pain or VAS pain during the 2-year follow-up. The subgroup
analysis of patients with deﬁnite radiographic OA (K&L2) at baseline
(n ¼ 108) showed a signiﬁcant association between loguCTX-II and VAS
pain (coefﬁcient 16.7; 95% CI 7.3-26.1). The cross-sectional association
between loguCTX-II andWOMAC painwas not signiﬁcant in the deﬁnite
radiographic OA group, nor were the associations between loguCIIM
and WOMAC pain or VAS pain. In the group with minimal radiographic
OA at baseline (n ¼ 114), no associations were found between loguCTX-
II, loguCIIM and the pain scores.
Figure 1. Extracellular matrix degradation. Bovine FDC explants were
cultured with indicated treatments for 27 days. Supernatant were moni-
tored by biomarkers of cartilage degradation C2M, AGNx1 and AGNx2
(Nordic Bioscience A/S). Values are mean  SEM. One-way ANOVA was
used to compare each bar with its respective W/O. *P < 0.05, **P < 0.01.
Abstracts / Osteoarthritis and Cartilage 22 (2014) S57–S489S76Conclusions: This study shows that in patients with hip OA the urinary
biochemical markers uCTX-II and uCIIM are not cross-sectionally
associated with hip pain during the 2-year follow-up. However, the
uCTX-II level at baseline could predict a progressive or moderate hip
pain trajectory over a two-year follow-up period.
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EXTRACELLULAR MATRIX CHANGES IN RESPONSE TO RECOMBINANT
HUMAN FIBROBLAST GROWTH FACTOR 18 STUDIED IN EX VIVO
CULTURES OF ARTICULAR CARTILAGE
D. Reker y, T. Christiansen z, M. Karsdal y, A. Bay-Jensen y. yNordic BioSci.
A/S, Herlev, Denmark; zOrthopedic Dept., Gentofte Univ. Hosp., Hellerup,
Denmark
Purpose: Osteoarthritis (OA) is a degenerative disease with high
prevalence, creating an unmet medical need for drugs to regenerate
cartilage. A promising candidate for a novel disease modifying osteo-
arthritis drug (DMOAD) is Sprifermin, a truncated form of ﬁbroblast
growth factor 18 (FGF18). Sprifermin has been demonstrated to
increase cartilage volume in the knees of OA patients, but surprisingly
little is known about the mode of action behind its anabolic effects.
The few studies published indicate that full-length FGF18 induces
cartilage formation by increasing chondrocyte proliferation, resulting
in increased overall matrix production by the larger population of
chondrocytes. Our hypothesis is that matrix degradation is initially
needed during this process in order to expand the lacunae and make
room in the matrix for the new chondrocytes. Accordingly, the aim of
this study was to characterize the changes in matrix degradation
occurring in response to direct stimulation with recombinant human
(rh) FGF18.
Methods: Full depth cartilage explants (FDCex) punched from bovine
articular cartilage were cultured for 27 days. In replicates of six, the
FDCex were treated with various concentrations of full-length rhFGF18
(1, 10, 50, 100 or 500 ng/mL rhFGF18), an anabolic cytokine as positive
control for cartilage formation (100 ng/mL IGF-I), or culture media
without treatment as negative control (W/O). Supernatants were har-
vested and replaced 3 times weekly. Cell viability was measured using
AlamarBlue at day 27. Biomarkers released to the supernatant were
measured using the following well-described ELISA; C2M and AGNx2
reﬂecting matrix metalloproteinase (MMP)-mediated degradation of
type II collagen and aggrecan, respectively, AGNx1 reﬂecting aggreca-
nase-mediated degradation of aggrecan, and C-Col10 reﬂecting chon-
drocyte hypertrophy. Mean values and standard error of the mean
(SEM) were compared using one-way ANOVA assuming normal dis-
tribution. Signiﬁcance levels are indicated by asterisks; *P < 0.05, **P <
0.01.
Results: To evaluate the changes in matrix degradation occurring in
the FDCex in response to direct stimulation with rhFGF18, three
different biomarkers of matrix degradation were quantiﬁed (ﬁgure
1). According to C2M, MMP-mediated type II collagen degradation is
signiﬁcantly decreased in response to  50 ng/mL rhFGF18 from day
11 onward (P < 0.05). Likewise, AGNx2 indicates a slight decrease
in MMP-mediated aggrecan degradation in response to  50 ng/mL
rhFGF18 from day 18 onward, although not signiﬁcant. On the
contrary, AGNx1 reveals increased aggrecanase-mediated aggrecan
degradation in response to  10 ng/mL rhFGF18 at day 25, although
only signiﬁcant for 50 ng/mL rhFGF18 (P < 0.05). Evaluation of the
chondrocytic changes occurring in response to rhFGF18, reveal a
dose-dependent increase in cell viability measured at day 27, and
no indication of hypertrophic cell differentiation, as assessed by C-
Col10.
Conclusions: The data presented here indicate that direct stim-
ulation of articular cartilage with rhFGF18 leads to decreased gen-
eration of MMP-mediated cleavage fragments of type II collagen and
aggrecan, but increased generation of the aggrecanase-mediated
cleavage fragment of aggrecan. Interestingly, AGNx2 is believed to be
a marker of cartilage degradation with impaired repair capacity,
whereas AGNx1 is considered a marker of reversible form cartilage
degradation. Accordingly, the increased AGNx1 could indicate the
matrix degradation needed for expansion of the lacunae, which
according to our hypothesis is needed to initiate the process of
cartilage formation. Clarifying the steps of this process is highly
important for the understanding of how a potential novel DMOAD is
affecting the tissue.121
URINE CROSSLINKED TELOPEPTIDE OF TYPE II COLLAGEN
PREDICTED OSTEOARTHRITIS PROGRESSION
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Purpose: The gold standard for assessing joint damage is still the plain
radiograph and this method only provides a historical view of the
skeletal damage that has already occurred. We cannot predict OA pro-
gression from the radiograph. In contrast, biomarkers are candidates to
predict an event that would occur in OA. One of the primary disease
processes of osteoarthritis is degradation of the type II collagen, which
is most abundant and highly speciﬁc for cartilage tissue. Crosslinked
telopeptide of type II collagen (CTX-II) was one of the speciﬁc marker of
type II collagen degradation in cartilage. Monitoring urine (u) CTX-II
was considered to be a potential biomarker in knee OA. It is reported
that uCTX-II was correlated with prevalence of radiographic OA and
higher uCTX-II had a increasing risk of having OA. However, there were
few reports about its role for prediction of OA progression. The purpose
of this study was to investigate whether uCTX-II could predict OA
progression.
Methods: This prospective cohort study protocol was approved by the
institutional review board of our university. One hundred and fourteen
painful medial knee OA patients were enrolled in this study. Some of the
patients were excluded due to data and follow up missing. Ninety one
patients (71.5y in average, men/female: 9/82) were analyzed. The basal
characteristics of the patients and a standing, extended antero-
